Apple v. Fintiv: The Six Factors That Reshaped PTAB Institution

Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11 (P.T.A.B. Mar. 20, 2020), designated precedential on May 5, 2020, is the administrative decision that reshaped inter partes review strategy more than any court opinion of its era. In a short order, a panel of the Patent Trial and Appeal Board set out six factors for deciding when to exercise the Board’s discretion under 35 U.S.C. Section 314(a) to deny institution of an IPR because a parallel district-court or International Trade Commission proceeding is racing toward trial. For the next several years those factors, and the denials they produced, dominated the calculus of when and where to challenge a patent.

The order matters not because it broke new statutory ground but because it operationalized a discretionary power the Supreme Court had confirmed and turned it into a predictable, and to petitioners a threatening, screen. Understanding Fintiv means understanding both the six factors themselves and the extraordinary churn that has surrounded them since.

At a glance

• Case: Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11 (P.T.A.B. Mar. 20, 2020) (precedential)
• Decided: March 20, 2020, Patent Trial and Appeal Board panel; designated precedential May 5, 2020
• Holding: Paper 11 was an order authorizing supplemental briefing, not a denial. It articulated six non-dispositive factors, to be weighed holistically, for exercising Section 314(a) discretion to deny IPR institution in view of a parallel proceeding nearing trial.
• Companion decision: Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 15 (P.T.A.B. May 13, 2020) (informative), which applied the factors and denied institution.
• Status: As of July 2026, the framework has been reshaped by subsequent USPTO director guidance, with proposed rulemaking still pending, though its underlying efficiency concern endures.

The discretion behind the doctrine

The America Invents Act created inter partes review as a faster, cheaper administrative path to challenge patent validity, and 35 U.S.C. Section 314(a) provides that the Director may not institute review unless the petition shows a reasonable likelihood that the petitioner will prevail on at least one claim. The Supreme Court read that “may” as conferring genuine discretion. Cuozzo Speed Technologies, LLC v. Lee, 579 U.S. 261 (2016), held that Section 314(d) bars judicial review of the Board’s determination whether to institute, at least where the challenge is closely tied to the application of the institution statute. SAS Institute Inc. v. Iancu, 584 U.S. 357 (2018), confirmed that Section 314(a) gives the Director discretion on the question whether to institute review at all, though it rejected the claim that this discretion extends to instituting on only some challenged claims, and it held that review under the Administrative Procedure Act remains available when the agency exceeds its statutory authority. That discretion over whether to institute is the engine of Fintiv. If the Director may decline to institute even a meritorious petition, the question becomes when the Director should, and parallel litigation supplies one powerful answer.

The efficiency rationale is intuitive. By statute the Board must issue a final written decision within one year of institution, extendable by up to six months for good cause, so the Board’s ruling is normally about a year out when it decides whether to institute. If a district court will try the same validity questions to a jury months before the Board would rule, instituting review risks duplicative effort, wasted resources, and potentially conflicting outcomes. The Board had gestured at these concerns in earlier precedential orders such as NHK Spring Co. v. Intri-Plex Technologies, Inc., and Fintiv gathered them into a structured test.

The six factors

The Fintiv order directs the Board to weigh six factors, none dispositive, in a holistic assessment of whether efficiency and the integrity of the system favor denial:

1. Whether the court granted a stay, or evidence suggests a stay may be granted, if the Board institutes review.
2. The proximity of the court’s trial date to the Board’s projected statutory deadline for a final written decision.
3. The investment in the parallel proceeding by the court and the parties at the time of the institution decision.
4. The overlap between the issues raised in the petition and in the parallel proceeding.
5. Whether the petitioner in the IPR and the defendant in the parallel proceeding are the same party.
6. Other circumstances that impact the Board’s exercise of discretion, including the merits of the petition.

Paper 11 itself decided nothing about institution. It was an order on the conduct of the proceeding: because Fintiv’s preliminary response raised discretionary denial based on a newly set November 16, 2020 trial date, the panel set out these factors and authorized supplemental briefing so Apple could respond. The order framed the analysis around efficiency, fairness, and the integrity of the patent system rather than the raw strength of the validity challenge, and directed the Board to take a holistic view rather than treat any single factor as controlling.

The denial came in a separate decision, Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 15 (P.T.A.B. May 13, 2020) (designated informative July 13, 2020), often called Fintiv II. By then the November trial date was gone: the parties had agreed to an amended scheduling order setting jury trial for March 8, 2021, roughly two months before the Board’s final written decision would have been due. The Board treated that proximity as weighing only “somewhat” in favor of denial, and rested its conclusion on the combination of factors: the district court had issued a claim construction order, the same claims were challenged on the same prior art in both forums, the petitioner and the district-court defendant were the same party, and the panel saw “some weaknesses” in Apple’s merits arguments. Weighing those holistically, the Board denied the petition and instituted no review.

Why petitioners feared it

The practical consequence was that accused infringers could lose their chosen validity forum through no fault of their patent challenge. A petition could clear the reasonable-likelihood merits bar and still be denied because the district court’s docket happened to move fast, a factor largely outside the petitioner’s control and often driven by the patent owner’s choice of venue. Districts known for rapid trial settings, particularly the Western District of Texas at the height of the trend, became magnets for patent owners precisely because a looming trial date could trigger a Fintiv denial.

Petitioners adapted. The most important workaround was the Sotera stipulation, named for the Board’s decision in Sotera Wireless, Inc. v. Masimo Corp., in which a petitioner promises not to pursue in the parallel litigation any invalidity ground that it raised or reasonably could have raised in the IPR. Such a stipulation drains the overlap factor of force and greatly reduces the risk of a Fintiv denial. Later USPTO guidance in June 2022 embraced Sotera stipulations, instructed the Board not to deny institution based on a parallel proceeding when the petition presented compelling merits, and cautioned against relying on unreliable trial-date projections.

The churn since 2020

Fintiv has been one of the most unstable doctrines in patent law, revised repeatedly as USPTO leadership changed. The 2022 director guidance softened it. On February 28, 2025, Acting Director Coke Morgan Stewart rescinded that guidance memo, and on March 26, 2025 she introduced a bifurcated institution process, splitting discretionary considerations from the merits and letting patent owners request discretionary denial directly from the Director, with new factors such as a patent owner’s settled expectations. After John Squires was confirmed as Director on September 18, 2025, the office pushed further: in October 2025 he stopped delegating merits-based institution determinations to Board panels, deciding them himself and issuing summary institution notices. On October 17, 2025 the office also published a notice of proposed rulemaking that would replace the discretionary Fintiv balancing with bright-line bars to institution, including a bar where a parallel trial or ITC determination is more likely than not to precede the final written decision. That proposal remains a proposal: as of July 2026 no final rule has issued. What has changed the practice on the ground is the guidance, not the rules. The specific six-factor test of the original order no longer operates as written, but the efficiency concern it identified continues to drive how and whether the Board takes cases.

Open questions

The central unresolved question is stability itself. Because Fintiv rests on discretionary policy rather than statute, each administration can and has rewritten it, leaving petitioners and patent owners to plan around a moving target. Whether the proposed 2025 rules are finalized at all, and if so whether they survive judicial challenge, is unresolved as of July 2026, as is whether concentrating institution decisions in the Director is consistent with the statute and with due process. The unreviewability of institution decisions under Cuozzo limits the courts’ ability to police the framework, which pushes the fight into rulemaking and mandamus. And the interaction between discretionary denial and the AIA’s estoppel provisions continues to complicate the strategic picture for anyone choosing between the Board and the district court.

Implications for inventors and businesses

• Venue and timing are strategic weapons. Patent owners can influence the Board’s discretion by choosing fast districts and pressing for early trial dates, so accused infringers should file IPR petitions promptly to blunt the proximity factor.
• Consider a Sotera-style stipulation. Petitioners worried about discretionary denial can reduce issue overlap by stipulating not to raise the same invalidity grounds in the parallel case, trading district-court arguments for a better shot at institution.
• Track the policy, not just the precedent. Because the framework has changed repeatedly through 2025 and 2026, both sides should monitor current USPTO guidance and rulemaking rather than relying on the original Fintiv order.
• Model the parallel case honestly. The efficiency rationale means the real question is how far the litigation will progress before the Board would rule, so realistic scheduling assumptions belong at the center of any institution-stage strategy.

Frequently asked questions

What is a Fintiv discretionary denial? A Fintiv discretionary denial is a decision by the Patent Trial and Appeal Board to decline to institute an inter partes review under 35 U.S.C. Section 314(a) because a parallel district-court or ITC case involving the same patent is far enough along that instituting review would be inefficient. The Fintiv order set out six factors the Board weighs holistically to make that call.

What are the six Fintiv factors? They are: whether a stay exists or is likely if review is instituted; the proximity of the parallel trial date to the Board’s deadline for a final written decision; the investment already made in the parallel proceeding; the overlap of issues between the petition and the litigation; whether the petitioner and the parallel-proceeding defendant are the same party; and other circumstances, including the strength of the petition’s merits.

Is Fintiv still in force in 2026? The original 2020 Fintiv framework has been repeatedly revised. As of July 2026, the six-factor order no longer operates as written, having been overtaken by a series of USPTO director actions: the February 2025 rescission of the 2022 Fintiv guidance memo, a bifurcated institution process introduced in March 2025 that routes discretionary-denial requests to the Director, and the Director’s decision in October 2025 to make institution determinations himself. An October 2025 notice of proposed rulemaking would go further and replace the balancing test with bright-line bars, but it is still only a proposal and no final rule has issued. The core concern Fintiv identified, parallel-litigation efficiency, still drives PTAB institution practice.

Authorities and sources

• Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 11 (P.T.A.B. Mar. 20, 2020) (USPTO PDF)
• Apple Inc. v. Fintiv, Inc., IPR2020-00019, Paper 15 (P.T.A.B. May 13, 2020) (informative), denying institution (USPTO PDF)
• “Revision to Rules of Practice Before the Patent Trial and Appeal Board,” 90 Fed. Reg. 48335 (proposed Oct. 17, 2025) (govinfo PDF)
• Finnegan, “PTAB Designates Decision on Discretionary Denial as Precedential”
• Winston & Strawn, “Precedential Opinion: Board weighs six factors in discretionary denial analysis”
• USPTO, “USPTO rescinds memorandum addressing discretionary denial procedures”
• Morgan Lewis, “From Stewart to Squires: The PTAB’s First-Year Reset in IPRs and PGRs”
• 35 U.S.C. Section 314, Institution of inter partes review (Cornell LII)